News | Heart Valve Technology | February 23, 2016

FDA OKs TAVR CoreValve Trial for Low-risk Surgical Patients

Self-expanding TAVR system will be tested in low-surgical-risk aortic stenosis patients

Medtronic, CoreValve Evolut R system, FDA expanded indication trial

February 23, 2016 — The U.S. Food and Drug Administration (FDA) approved an expanded indication trial for low-risk surgical patients using Medtronic’s CoreValve Evolut R System transcatheter aortic valve replacement (TAVR) system. Patients with aortic stenosis, who are at a low surgical mortality risk as determined by a heart team, will be enrolled in the trial.

Enrollment for the investigational device exemption (IDE) trial is expected to begin during the spring of 2016 and will include 1,200 patients with severe aortic stenosis who have a less than 3 percent risk of mortality, as determined by a heart team. The trial will enroll low-risk patients from up to 80 clinical sites with 1:1 randomization to receive the Evolut R System or undergo open-heart surgery (surgical aortic valve replacement or SAVR). The IDE is designed as an adaptive trial with a primary endpoint of all-cause mortality or disabling stroke. The trial has a two-year endpoint and allows for a one-year analysis for early FDA submission. Additionally, the trial will include a sub-study of leaflet mobility in 400 patients.

“This trial comes on the heels of data showing patients who underwent TAVR with this self-expanding platform demonstrated superior survival benefit — with low and stable stroke rates — compared to SAVR patients,” said Michael Reardon, M.D., professor of cardiothoracic surgery at Houston Methodist DeBakey Heart & Vascular Center and principal investigator of the IDE study. “This study is an important next step in developing robust clinical evidence to help heart teams understand the potential benefits of TAVR in a broader patient population.”

The Evolut R system is optimized to increase conformability and sealing at the annulus, while maintaining supra-annular valve positioning for improved blood flow and hemodynamic performance. The valve is delivered through the EnVeo R Delivery Catheter System, which features an InLine Sheath that provides what Medtronic calls the lowest profile on the market (14 Fr equivalent, less than 1/5 inch). The low profile enables treatment of patients with vessels down to 5mm through the preferred transfemoral access route, and may minimize the risk of major vascular complications in some patients.

The transcatheter valve and the delivery catheter system were FDA-approved for commercial use in the United States in June 2015. It is also available in Europe and other countries that recognize the CE mark. 

In January, the FDA approved a similar IDE trial examining the use of the Edwards Lifesciences Sapien 3 TAVR device in low-risk surgical patients. 

 

For more information: www.medtronic.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init